Skip to main content

Drug Interactions between dopamine and V-Gan-50

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DOPamine promethazine

Applies to: dopamine and V-Gan-50 (promethazine)

GENERALLY AVOID: Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors. Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect. Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.

MANAGEMENT: Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents. Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.

References

  1. Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC "Chlorpromazine: a study of its action on the circulation in man." Lancet 2 (1954): 614-7
  2. Ginsburg J, Duff RS "Effect of chlorpromazine on adrenaline vasoconstriction in man." Br J Pharmacol 11 (1956): 180-5
  3. "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham PROD (2002):
  4. "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories PROD (2001):
  5. "Product Information. Navane (thiothixene)." Roerig Division PROD (2001):
  6. Lear E, Chiron AE, Pallin IM "A clinical study of mechanisms of action of chlorpromazine." JAMA 163 (1957): 30-6
  7. Gonzalez ER "Catecholamine selection for vasopressor-dependent patients." Clin Pharm 7 (1988): 493, 496
  8. "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals PROD (2001):
  9. Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7
  10. "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company PROD (2001):
  11. "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals PROD (2001):
  12. "Product Information. Moban (molindone)." Gate Pharmaceuticals PROD (2001):
  13. "Product Information. Torecan (thiethylperazine)." Roxane Laboratories Inc PROD (2001):
  14. "Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals PROD (2001):
  15. "Product Information. Loxitane C (loxapine)." Apothecon Inc (2022):
  16. Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S "Chronic chlorpromazine administration: some pharmacological and psychological effects in man." Clin Pharmacol Ther 6 (1965): 575-86
  17. "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb (2002):
  18. "Product Information. Invega (paliperidone)." Janssen Pharmaceuticals (2007):
View all 18 references

Switch to consumer interaction data

Drug and food interactions

Moderate

promethazine food

Applies to: V-Gan-50 (promethazine)

GENERALLY AVOID: Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment. Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines. The two drugs probably act on different sites in the brain, although the exact mechanism of the interaction is not known.

MANAGEMENT: Patients should be advised to avoid alcohol during phenothiazine therapy.

References

  1. Lutz EG "Neuroleptic-induced akathisia and dystonia triggered by alcohol." JAMA 236 (1976): 2422-3
  2. Freed E "Alcohol-triggered-neuroleptic-induced tremor, rigidity and dystonia." Med J Aust 2 (1981): 44-5

Switch to consumer interaction data

Moderate

DOPamine food

Applies to: dopamine

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
  3. "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
  4. "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
  5. "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
  6. "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
  7. "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer